ADMA Biologics (NASDAQ:ADMA) Given “Neutral” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of ADMA Biologics (NASDAQ:ADMA) in a research report released on Thursday morning, MarketBeat reports.

Other equities research analysts have also issued research reports about the company. Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $8.29 on Thursday. The firm’s fifty day simple moving average is $15.76 and its 200 day simple moving average is $16.47. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $25.67. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 13.82 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period in the prior year, the firm earned $0.46 EPS. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. As a group, equities research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steve Elms purchased 7,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds have recently bought and sold shares of the business. State Street Corp raised its position in shares of ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after purchasing an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP grew its position in shares of ADMA Biologics by 27.0% during the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after buying an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP grew its position in shares of ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after buying an additional 1,886,105 shares in the last quarter. Capital Research Global Investors increased its stake in shares of ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Finally, Nuveen LLC increased its stake in shares of ADMA Biologics by 3.5% in the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after buying an additional 202,245 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Technical / analyst support: ADMA was added to Zacks’ Rank #1 (Strong Buy) list and a Zacks piece argued the recent selloff left the stock oversold and ripe for a turnaround — a potential catalyst if sentiment stabilizes. New Strong Buy Stocks for March 25th
• Positive Sentiment: Technical rebound argument: Zacks highlighted ADMA’s heavy recent selling (down ~27% in four weeks) and suggested oversold technicals could prompt a bounce, which may attract short‑term buyers. Down 27% in 4 Weeks
• Neutral Sentiment: Company response: ADMA publicly disputed the Culper Research short report, calling its claims speculative and inaccurate and saying the company and board will review the assertions — this rebuttal may limit some immediate panic but hasn’t arrested the selloff. ADMA Addresses Short Seller Report
• Neutral Sentiment: Unusual options activity: volume of ADMA call options spiked ~848% intraday — this could reflect speculative bets or positioning by traders expecting a bounce or volatility, but it’s not a clear directional endorsement. (No article link available.)
• Negative Sentiment: Short‑seller report and market reaction: Culper Research published a report alleging channel‑stuffing and an undisclosed related‑party distributor, claiming ADMA’s reported growth is overstated; that report triggered the initial selloff and credibility concerns. Short Seller Report Coverage / Investor Alerts
• Negative Sentiment: Analyst action: Cantor Fitzgerald reacted following the short report (coverage noted in market media), which extended selling pressure and reduced near‑term analyst support. Cantor Fitzgerald Downgrade
• Negative Sentiment: Multiple shareholder/law‑firm investigations: Several firms (Glancy Prongay Wolke & Rotter, BFA Law, Holzer & Holzer, Pomerantz, Frank R. Cruz, Ademi LLP and others) announced inquiries into potential securities claims tied to the short‑seller allegations — increasing legal risk and prolonging negative sentiment. BFA Law Investigation Notice Glancy Investigation
• Negative Sentiment: Price and market flow: coverage and alerts have driven heavy selling and large intraday volume; short‑term downside is being reinforced by litigation risk and analyst downgrades even as the company disputes the claims. ADMA Stock Slides

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.